Treatment of acute myeloid leukemia with olutasidenib, venetoclax, and a hypomethylating agent
CL202600040A1Pending Publication Date: 2026-07-03RIGEL PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202600040
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-03
- Filing Date
- 2026-01-07
- Publication Date
- 2026-07-03
Abstract
Methods are provided for treating a subject with a hematologic neoplasm or preneoplasm involving the administration of an effective amount of olutasidenib, venetoclax, and a hypomethylating agent. In some cases, the patient has an IDH1 mutation.
Need to check novelty before this filing date? Find Prior Art